Open Orphan plc changed its name to hVIVO plc on 26 October 2022, learn more
here
.
About Us
About hVIVO
Leadership Team
Our Companies
Key Stats
History
Services
Challenge Trials
RSV
Influenza
COVID-19
HRV
Malaria
Asthma & COPD
Laboratory Services
Assay Development
Field Trial Bio-logistics
Cell Based Assays
Molecular Services
Compound Efficacy & VRM
Biomarker Analysis
Phase II-III Clinical Trials
Vaccine Phase II-III Trials
Articles & Research
News & Media
Regulatory News
Media Coverage
Media Press Kit
Video Library
Events
Investors
New
Investors
Regulatory News & Email Alerts
Results Centre
Share Price Information
Events & Presentations
Environmental, Social & Governance
AIM Rule 26
Advisors
Documents
Corporate Governance
Volunteers
Careers
Contact Us
Contact Us
07 Mar 2023
Go Back
EMA’s updated guideline to include broader coverage on Human Challenge Trials
Share this:
Other recent posts
Blog
Advantages to Centralising Laboratory Services at hVIVO
Clinical field studies are a critical part of the drug development and approval process. They are conducted to evaluate the safety, immunogenicity, and efficacy of a new drug. These studies...
Read more
Blog
Advantages of Human Challenge Studies (Part 1)
Human challenge studies or controlled human infection model (CHIM) studies are Phase Ib or Phase IIa clinical trials, in which study participants, i.e. healthy volunteers, are deliberately exposed to infectious...
Read more
If you’re a potential customer, job seeker, health professional or an investor, find out how hVIVO can help you.
Contact hVIVO
twitter
facebook
envelope
linkedin
angle-down
xing
paper-plane
pinterest-p
whatsapp
commenting
meetup
chevron-down